+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antibodies"

From
Vitiligo - Pipeline Insight, 2025 - Product Thumbnail Image

Vitiligo - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Lupus Nephritis - Pipeline Insight, 2025 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Scleroderma - Pipeline Insight, 2025 - Product Thumbnail Image

Scleroderma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
From
From
From
PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Psoriatic Arthritis - Pipeline Insight, 2025 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Alopecia - Pipeline Insight, 2025 - Product Thumbnail Image

Alopecia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Toll-Like Receptor Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Toll-Like Receptor Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 150 Pages
  • Global
From
Atopic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Atopic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Microbiome Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Microbiome Disease- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Epidermolysis Bullosa - Pipeline Insight, 2025 - Product Thumbnail Image

Epidermolysis Bullosa - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Systemic Lupus Erythematosus - Pipeline Insight, 2025 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Myositis - Pipeline Insight, 2025 - Product Thumbnail Image

Myositis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Crohn's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Crohn's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025 - Product Thumbnail Image

Graft Versus Host Disease (GvHD) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Loading Indicator

The Antibodies market is a subset of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Antibodies are proteins produced by the body to fight off foreign substances, such as bacteria and viruses. They are used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and cancer. Antibodies can be used in combination with other drugs, such as steroids, to reduce inflammation and improve symptoms. They can also be used to target specific cells or proteins in the body, allowing for more targeted treatments. The Antibodies market is highly competitive, with a number of companies offering a variety of products. Companies such as AbbVie, Amgen, and Biogen are leading the way in developing and marketing antibodies for the treatment of immune-related conditions. Other companies, such as Genentech and Regeneron, are also active in the market, offering a range of products for different conditions. Show Less Read more